

Claims

Sub
1
2
3
4
5

1. A process for vitreous liquefaction comprising the steps of:
delivering a dose of a plasmin composition into a vitreous body of a
subject eye; and
incubating the plasmin composition in the vitreous body for a
predetermined amount of time.

2. The process of claim 1 wherein the delivering is by injection.

3. The process of claim 1 wherein the delivering is by infusion.

4. The process of claim 1 wherein the delivering is by sustained
release intraocular device.

5. The process of claim 1 wherein the plasmin composition
comprises human plasmin.

6. The process of claim 1 wherein the plasmin composition
comprises autologous human plasmin.

7. The process of claim 1 wherein the plasmin composition
comprises an accompaniment selected from the group consisting of: an
enzyme, a glycoprotein, a polysaccharide, an antibiotic, a pharmaceutically

1006834-020602

TMT-10902/04
20131gs/am

4 acceptable diluent, a pharmaceutically acceptable adjuvant and a
5 pharmaceutically acceptable carrier.

1 8. The process of claim 1 further comprising the step of delivering
2 a plasmin inhibitor.

1 9. The process of claim 1 wherein the subject eye has a
2 pathological condition.

1 10. The process of claim 9 wherein the pathological condition is
2 selected from the group consisting of: diabetic retinopathy, macular hole,
3 macular pucker, intraocular infection, foreign intraocular material and retinal
4 detachment.

1 11. The process of claim 1 wherein the dose of a plasmin
2 composition comprises between 0.01 and 5.0 units of plasmin.

1 12. The process of claim 1 wherein the dose of a plasmin
2 composition comprises between 0.1 and 1.0 units of plasmin.

1 13. The process of claim 1 wherein the predetermined amount of
2 time is ten minutes and two hours.

20060214.020602

1 *Sub*
2 *A2*
3 14. A process for vitreous liquefaction comprising the steps of:
4 delivering a dose of a plasmin composition comprising autologous
5 plasmin into a vitreous body of a subject eye; and
6 incubating the plasmin composition in the vitreous body for a
7 predetermined amount of time.

1 15. The process of claim 14 wherein the delivering is by injection.

1 16. The process of claim 14 wherein the delivering is by infusion.

1 17. The process of claim 14 wherein the delivering is by sustained
2 release intraocular device.

1 18. The process of claim 14 wherein the plasmin composition
2 comprises an accompaniment selected from the group consisting of: an
3 enzyme, a glycoprotein, a polysaccharide, an antibiotic, a pharmaceutically
4 acceptable diluent, a pharmaceutically acceptable adjuvant and a
5 pharmaceutically acceptable carrier.

1 19. The process of claim 14 further comprising the step of
2 delivering a plasmin inhibitor.

TMT-10902/04
20131gs/am

1 20. The process of claim 14 wherein the subject eye has a
2 pathological condition.

1 21. The process of claim 20 wherein the pathological condition is
2 selected from the group consisting of: diabetic retinopathy, macular hole,
3 macular pucker, intraocular infection, foreign intraocular material and retinal
4 detachment.

1 22. The process of claim 14 wherein the dose of a plasmin
2 composition comprises between 0.01 and 5.0 units of plasmin.

1 23. The process of claim 14 wherein the dose of a plasmin
2 composition comprises between 0.1 and 2.0 units of plasmin.

1 24. The process of claim 14 wherein the predetermined amount of
2 time is ten minutes and two hours.

Add a3